Pesquisar
Ironwood Pharmaceuticals Inc
IRWDAdicionar à lista de desejos
4.190USD
-0.080-1.87%
Fechamento 09-24 16:00（ET）
689.72MValor de mercado
6.65P/L TTM
Sobre o Ironwood Pharmaceuticals Inc Empresa
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Ironwood Pharmaceuticals Inc Perfil
Código da empresaIRWD
Nome da EmpresaIronwood Pharmaceuticals Inc
Data de listagemFeb 03, 2010
CEOMccourt (Thomas A)
Número de funcionários253
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 03
Endereço100 Summer Street, Suite 2300
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02110
Telefone16176217722
Sitehttps://www.ironwoodpharma.com/
Código da empresaIRWD
Data de listagemFeb 03, 2010
CEOMccourt (Thomas A)
Executivos da empresa Ironwood Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Mr. Ronald Silver
Mr. Ronald Silver
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
Interim Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller
271.90K
-47.04%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
676.90K
+9.38%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
428.32K
+31.89%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
327.55K
+1.13%
Perguntas frequentes
Quem são os cinco principais acionistas de Ironwood Pharmaceuticals Inc?
Os cinco principais acionistas de Ironwood Pharmaceuticals Inc são: Dr. Mark G. Currie, Ph.D.
Quantas instituições possuem ações da Ironwood Pharmaceuticals Inc (IRWD)?
Em 2026Q1, 549 instituições possuíam ações da Ironwood Pharmaceuticals Inc, com valor de mercado aproximado de 166.41M, representando 101.09% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -30766447.00.